Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RH5.1/Matrix-M Phase Ib in Tanzania
NCT04318002Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jan 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RH5.1 + Matrix-M in Plasmodium falciparum malaria, sponsored by University of Oxford. Primary endpoints: Occurrence of solicited symptoms, Occurrence of unsolicited symptoms and 1 more. Started Jan 2021; status: completed.
02
Drugs
RH5.1 + Matrix-M
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT04318002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318002.